Merck (MRK) is scheduled to report first-quarter earnings on April 30, during market hours, with analysts expecting a strong performance from Keytruda and Winrevair. The consensus EPS Estimate is -$1.

Merck stock up 11% YTD as Keytruda growth, pipeline gains and M&A lift outlook, but patent risks, Gardasil slump and generics weigh on near-term upside.

By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, Germany’s Merck KGaA and Japan's Ono Pharmaceutical for an experimental ...

After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect ...

Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s ...

Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for American patients.

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal ...

Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...

By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, ...